论文部分内容阅读
目的:观察卡维地洛对不同海拔高度慢性收缩性心力衰竭患者的心功能影响情况。方法:将120例心力衰竭患者按海拔分为高海拔组和低海拔组,再根据用药情况分为卡维地洛组和对照组。方法:所有组均予心力衰竭常规治疗,治疗组加用卡维地洛,治疗前后测定四组射血分数,左心室收缩末期容积(LVESV)及左心室舒张期容积,并进行临床疗效评价。结果:四组治疗前各观察项无显著性差异,治疗后LVESV较治疗前均明显改善,P<0.01;低海拔治疗组治疗后LVESV显著低于高海拔组(t=2.026,P<0.05)。低海拔治疗组临床总有效率分别为86.7%和67.9%,明显高于对照组(2=3.962,P<0.05),高海拔治疗组与对照组临床总有效率分别为71.9%和53.3%,两者无显著性差异。结论:卡维地洛能明显改善慢性收缩性心力衰竭患者的临床症状和心功能,低海拔组治疗效果略好于高海拔组。
Objective: To observe the influence of carvedilol on cardiac function in patients with chronic systolic heart failure at different altitudes. Methods: 120 cases of heart failure patients were divided into high altitude group and low altitude group according to the altitude, and then divided into carvedilol group and control group according to the medication situation. Methods: All the patients were given conventional treatment of heart failure. The treatment group was given carvedilol, and the ejection fraction, left ventricular end-systolic volume (LVESV) and left ventricular diastolic volume were measured before and after treatment. Clinical efficacy was evaluated. Results: There was no significant difference between the four groups before treatment. The LVESV of the four groups were significantly improved after treatment (P <0.01), and the LVESV of the low altitude group was significantly lower than that of the high altitude group (t = 2.026, P <0.05) . The total clinical effective rates in low altitude group were 86.7% and 67.9%, respectively, which were significantly higher than those in control group (2 = 3.962, P <0.05). The total effective rates in high altitude group and control group were 71.9% and 53.3% , No significant difference between the two. Conclusion: Carvedilol can significantly improve the clinical symptoms and cardiac function in patients with chronic systolic heart failure. The therapeutic effect of low-altitude group is slightly better than that of high-altitude group.